Back to Search Start Over

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Authors :
Olivier Godeaux
David Marrupe Gonzalez
Lidia Oostvogels
Kyung Hae Jung
Marta López-Fauqued
David Farrugia
Bruno Salaun
Thomas C. Heineman
Emmanuel Di Paolo
Constanza Maximiano Alonso
Shelly A. McNeil
Ignacio Delgado Mingorance
Enrique Grande
Belen Rubio-Viqueira
Javier Puente
Laura Campora
Hartmut Kristeleit
Peter Vink
Juan Francisco Rodriguez Moreno
Mohamed El Idrissi
Sarah Lowndes
Source :
Cancer. 125:1301-1312
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

Background The adjuvanted recombinant zoster vaccine (RZV) has demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age and 68% efficacy in autologous hematopoietic stem cell transplant recipients ≥18 years of age. We report the immunogenicity and safety of RZV administered to patients with solid tumors (STs) before or at the start of a chemotherapy cycle. Method In this phase 2/3 observer-blind, multicenter study (NCT01798056), patients with STs who were ≥18 years of age were randomized (1:1) to receive 2 doses of RZV or placebo 1-2 months apart and stratified (4:1) according to the timing of the first dose with respect to the start of a chemotherapy cycle (first vaccination 8-30 days before the start or at the start [±1 day] of a chemotherapy cycle). Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4+ T cell frequencies, and vaccine response rates (VRRs) were assessed 1 month after dose 1 and 1 and 12 months after dose 2. Reactogenicity and safety were assessed in the total vaccinated cohort through 12 months after dose 2. Results There were 232 participants in the total vaccinated cohort, 185 participants in the according-to-protocol cohort for humoral immunogenicity, and 58 participants in the according-to-protocol cohort for cell-mediated immunogenicity. Postvaccination anti-gE antibody concentrations, gE-specific CD4+ T cell frequencies and VRRs were higher in RZV recipients than in placebo recipients. Solicited adverse events (AEs) were more frequent among RZV recipients than placebo recipients. Incidence of unsolicited AEs, serious AEs, fatalities, and potential immune-mediated diseases were similar between RZV and placebo recipients. Conclusion RZV was immunogenic in patients with STs receiving immunosuppressive chemotherapies. Humoral and cell-mediated immune responses persisted 1 year after vaccination. No safety concerns were identified.

Details

ISSN :
10970142 and 0008543X
Volume :
125
Database :
OpenAIRE
Journal :
Cancer
Accession number :
edsair.doi...........7f6b8cfdc840bb275c139e0bc2ab5bee
Full Text :
https://doi.org/10.1002/cncr.31909